Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of XZP-5955 in NTRK/ROS1+ Solid Tumors
NCT04996121Phase 2Recruiting
- Sponsor
- Xuanzhu Biopharmaceutical
- Start
- Dec 2021
- Primary completion
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of XZP-5955 in solid tumor and non-small cell lung cancer (NSCLC), sponsored by Xuanzhu Biopharmaceutical. Primary endpoints: Maximum Tolerated Dose at 24 days, Number of patients with adverse events and 1 more. Started Dec 2021; status: recruiting.
02
Drugs
XZP-5955
03
Conditions
solid tumornon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04996121.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04996121.